Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 14/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.39 |
| ▸ | REN | P00797 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PAK4 | O96013 | 1/20 | 0.34 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL601397 | 0.88 | HRH4 (0.65) | HRH4TP53MDM2MAPT | |
| SCHEMBL602615 | 0.85 | HRH4 (0.55) | HRH4KMT2AHRH3 | |
| SCHEMBL3570892 | 0.82 | HRH4 (0.54) | HRH4TP53MAPTHRH3 | |
| SCHEMBL603704 | 0.79 | HRH4 (0.76) | HRH4HRH3 | |
| SCHEMBL603983 | 0.78 | HRH4 (0.65) | HRH4TP53MDM2MEN1POLB | |
| SCHEMBL602208 | 0.78 | HRH4 (0.52) | HRH4TP53MDM2 | |
| SCHEMBL602207 | 0.74 | HRH4 (0.76) | HRH4HRH3 | |
| SCHEMBL6141962 | 0.72 | HRH4 (0.64) | HRH4TP53MAPT | |
| SCHEMBL604786 | 0.71 | HRH4 (0.70) | HRH4TP53MAPT | |
| SCHEMBL604296 | 0.69 | HRH4 (1.00) | HRH4POLBHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014130759-A1 | METHODS OF USING HISTAMINE RECEPTOR AGONISTS AND ANTAGONISTS | UNIVERSITY OF ROCHESTER (US) | 2014-08-28 | — | — | WO | claimed |
| US-7645758-B2 | Heterocyclic compounds | Janssen Pharmaceutica, N.Y. (BE) | 2010-01-12 | — | — | US | claimed |
| US-20070185120-A1 | Heterocyclic Compounds | JANSSEN PHARMACEUTICA, N.V. | 2007-08-09 | — | — | US | claimed |
| US-20160000777-A1 | METHODS OF USING HISTAMINE RECEPTOR AGONISTS AND ANTAGONISTS | UNIVERSITY OF ROCHESTER (US) | 2016-01-07 | — | — | US | disclosed |
| WO-2014130759-A1 | METHODS OF USING HISTAMINE RECEPTOR AGONISTS AND ANTAGONISTS | UNIVERSITY OF ROCHESTER (US) | 2014-08-28 | — | — | WO | disclosed |
| US-7645758-B2 | Heterocyclic compounds | Janssen Pharmaceutica, N.Y. (BE) | 2010-01-12 | — | — | US | disclosed |
| EP-1685406-A4 | ANALYZING HISTAMINE H sb 4 /sb RECEPTOR-MEDIATED EFFECTS IN WHOLE BLOOD | JANSSEN PHARMACEUTICA NV (BE) | 2008-11-12 | — | — | EP | disclosed |
| US-20080102476-A1 | Analyzing Histamine H4 Receptor-Mediated Effects In Whole Blood | KARLSSON LARS | 2008-05-01 | — | — | US | disclosed |
| US-20070185131-A1 | Heterocyclic Compounds | JANSSEN PHARMACEUTICA, N.V. | 2007-08-09 | — | — | US | disclosed |
| US-20070185120-A1 | Heterocyclic Compounds | JANSSEN PHARMACEUTICA, N.V. | 2007-08-09 | — | — | US | disclosed |
| US-7226938-B2 | Heterocyclic compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-06-05 | — | — | US | disclosed |
| EP-1685406-A2 | ANALYZING HISTAMINE H sb 4 /sb RECEPTOR-MEDIATED EFFECTS IN WHOLE BLOOD | Janssen Pharmaceutica N.V. (BE) | 2006-08-02 | — | — | EP | disclosed |
| EP-1543011-B1 | THIENOPYRROLYL AND FURANOPYRROLYL COMPOUNDS AND THEIR USE AS HISTAMINE H4 RECEPTOR LIGANDS | JANSSEN PHARMACEUTICA NV (BE) | 2006-05-03 | — | — | EP | disclosed |
| EP-1545596-A4 | USE OF HISTAMINE H4 RECEPTOR MODULATORS FOR THE TREATMENT OF ALLERGY AND ASTHMA | JANSSEN PHARMACEUTICA NV (BE) | 2005-12-28 | — | — | EP | disclosed |
| EP-1545596-A2 | USE OF HISTAMINE H4 RECEPTOR MODULATORS FOR THE TREATMENT OF ALLERGY AND ASTHMA | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-06-29 | — | — | EP | disclosed |
| EP-1543011-A2 | THIENOPYRROLYL AND FURANOPYRROLYL COMPOUNDS AND THEIR USE AS HISTAMINE H4 RECEPTOR LIGANDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-06-22 | — | — | EP | disclosed |
| WO-2005031308-A2 | ANALYZING HISTAMINE H4 RECEPTOR-MEDIATED EFFECTS IN WHOLE BLOOD | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-04-07 | — | — | WO | disclosed |
| WO-2004021999-A2 | USE OF HISTAMINE H4 RECEPTOR MODULATORS FOR THE TREATMENT OF ALLERGY AND ASTHMA | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-03-18 | — | — | WO | disclosed |
| WO-2004022537-A2 | THIENOPYRROLYL AND FURANOPYRROLYL COMPOUNDS AND THEIR USE AS HISTAMINE H4 RECEPTOR LIGANDS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-03-18 | — | — | WO | disclosed |
| US-20040048878-A1 | Cyclopentathienopyrroles and cyclopentafuranopyrroles for treating disorders and conditions mediated by the histamine H4 receptor, including allergic rhinitis. | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048878-A1 | Cyclopentathienopyrroles and cyclopentafuranopyrroles for treating disorders and conditions mediated by the histamine H4 receptor, including allergic rhinitis. | HRH4, HRH2, HRH1 | HRH4 1/4885TP53 3337/4885MDM2 3957/4885 |
| US-20070185131-A1 | Heterocyclic Compounds | HRH4, HRH2, HRH1 | HRH4 1/4885TP53 2547/4885MDM2 2387/4885 |
| US-20070185120-A1 | Heterocyclic Compounds | HRH4, HRH2, HRH1 | HRH4 1/4885TP53 2547/4885MDM2 2387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.